Literature DB >> 4506240

Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines.

E M Shevach, R Herberman, M M Frank, I Green.   

Abstract

The bone marrow-derived (B) lymphocyte can be identified by the presence of easily detectable surface immunoglobulin and a receptor for antigen-antibody-complement complexes (EAC'). Monocytes and macrophages also bear a receptor for EAC' and in addition possess a receptor for red cell-IgG complexes (EA). Thymus-derived (T) lymphocytes bear neither of these receptors. The cells of 15 patients with leukemia and 19 human lymphoblastoid cell lines were examined for the presence of the EAC' and EA receptors. Of the human leukemias studied, only the cells from the patients with chronic lymphatic leukemia (CLL) possess the EAC' receptor. The EA receptor could not be demonstrated on CLL cells; hence, CLL cells bear the lymphocyte EAC' receptor and by this criteria represent B lymphocytes. 12/19 of the cell lines studied could be classified as B lymphocytes by the presence of the EAC' receptor and absence of the EA receptor. 2/19 cell lines possessed both the EAC' and EA receptors and thus resemble the monocyte. 5/19 cell lines had no detectable receptor for EAC' or EA. The approach presented in this study for the classification of leukemias and cell lines as to their B lymphocyte, T lymphocyte, or monocyte origin may have useful diagnostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4506240      PMCID: PMC292349          DOI: 10.1172/JCI106999

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Characteristics of new cell lines derived from Burkitt lymphomas.

Authors:  J S Nadkarni; J J Nadkarni; P Clifford; G Manolov; E M Fenyö; E Klein
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

2.  Receptor sites of human monocytes for IgG.

Authors:  H Huber; H H Fudenberg
Journal:  Int Arch Allergy Appl Immunol       Date:  1968

3.  Isolation and characterization of free gamma chain of immunoglobulin produced by an established cell line of human myeloma cell origin. I. Gamma chain in culture medium.

Authors:  Y Matsuoka; Y Yagi; G E Moore; D Pressman
Journal:  J Immunol       Date:  1969-05       Impact factor: 5.422

4.  The IgG receptor: an immunological marker for the characterization of mononuclear cells.

Authors:  H Huber; S D Douglas; H H Fudenberg
Journal:  Immunology       Date:  1969-07       Impact factor: 7.397

5.  Morphology of cultured hematopoietic cells.

Authors:  G E Moore; H Kitamura; S Toshima
Journal:  Cancer       Date:  1968-08       Impact factor: 6.860

6.  The effect of temperature on the reactivity of guinea-pig complement with gamma G and gamma M haemolytic antibodies.

Authors:  M M Frank; T Gaither
Journal:  Immunology       Date:  1970-12       Impact factor: 7.397

7.  Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient.

Authors:  K Nilsson; H Bennich; S G Johansson; J Pontén
Journal:  Clin Exp Immunol       Date:  1970-10       Impact factor: 4.330

8.  Two distinct populations of peripheral lymphocytes in mice distinguishable by immunofluorescence.

Authors:  M C Raff
Journal:  Immunology       Date:  1970-10       Impact factor: 7.397

9.  Receptor sites for complement on certain human peripheral blood lymphocytes.

Authors:  G Michlmayr; H Huber
Journal:  J Immunol       Date:  1970-09       Impact factor: 5.422

10.  Receptors for complement of leukocytes.

Authors:  W H Lay; V Nussenzweig
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

View more
  65 in total

1.  Surface marker characteristics and Epstein-Barr virus studies of two established North American Burkitt's lymphoma cell lines.

Authors:  A L Epstein; W Henle; G Henle; J F Hewetson; H S Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1976-01       Impact factor: 11.205

2.  Demonstration that monocytes rather than lymphocytes are the insulin-binding cells in preparations of humah peripheral blood mononuclear leukocytes: implications for studies of insulin-resistant states in man.

Authors:  R H Schwartz; A R Bianco; B S Handwerger; C R Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

3.  Human lymphocyte complement receptors. Quantitative requirements for C3 of normal and chronic lymphocyte leukemia lymphocytes.

Authors:  G L Logue; H J Cohen
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

4.  Lack of subclass selection during density purification of human lymphocytes.

Authors:  P Häyry; T H Tötterman; A Ranki
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

5.  Description of the cells from the lymph nodes of patients with non-Hodgkin's lymphoma according to some B- and T-cell characteristics.

Authors:  G Stathopoulos; M Papamichail; E J Holborow; A J Davies
Journal:  Br J Exp Pathol       Date:  1977-02

6.  Characterization of non-Hodgkin's lymphomas using multiple cell markers. Immunologic, morphologic, and cytochemical studies of 72 cases.

Authors:  G S Pinkus; J W Said
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

7.  Subset derivation of T-cell acute lymphoblastic leukemia in man.

Authors:  E L Reinherz; L M Nadler; S E Sallan; S F Schlossman
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

8.  T lymphocytes bearing complement receptors in a patient with chronic lymphocytic leukaemia.

Authors:  H R Toben; R G Smith
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

9.  Inhibition of macrophage migration by muramyl peptides.

Authors:  S Nagao; A Tanaka; Y Yamamoto; T Koga; K Onoue; T Shiba; K Kusumoto; S Kotani
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

10.  Surface receptors on human haematopoietic cell lines.

Authors:  C Huber; C Sundström; K Nilsson; H Wigzell
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.